 |
|
|
| |
Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682) / Grazoprevir / Ruzasvir in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection Who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE)
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Heiner Wedemeyer1, David Wyles2, K. Rajender Reddy3, Anne Luetkemeyer4, Ira Jacobson5, John Vierling6, Stuart Gordon7, Ronald Nahass8, Stefan Zeuzem9, Janice Wahl10, Eliav Barr10, Bach-Yen Nguyen10, Michael Robertson10, Hee-Koung Joeng10, Hong Liu10, Patricia Jumes10, Frank Dutko10, Elizabeth Martin10
1Hannover Medical School, Hannover, Germany; 2 Denver Health Medical Center, Denver, CO, US; 3University of Pennsylvania, Philadelphia, PA, US; 4University of California, San Francisco, CA, US; 5Mount Sinai Beth Israel, New York, NY, US; 6Baylor College of Medicine, Houston, TX, US; 7Henry Ford Health System, Detroit, MI, US; 8ID Care, Hillsborough, NJ, US; 9Goethe University Hospital, Frankfurt, Germany; 10Merck & Co., Inc., Kenilworth, NJ, US
|
| |
|
|
|
|
|
